2. UroToday Home
  3. Categories

Bladder Cancer

Pathological Assessment of Morcellated Tissue after ERBT: Insights from a Two-Round Delphi Survey - Beyond the Abstract

Details
En bloc resection of bladder tumor (ERBT) is becoming increasingly popular because of several potential advantages over conventional trans urethral resection of bladder tumor (TURBT). Multiple studies have demonstrated better specimen quality, higher detrusor muscle detection rates, improved surgical margins, fewer bladder perforations, and lower catheterization time.1–5 Modern laser systems further facilitated the development of ERBT by allowing more controlled dissection with minimal bleeding and limited thermal damage to the specimen.6–8

EAU Guidelines on Nonmuscle-invasive Bladder Cancer (TaT1 and CIS) - A Summary of the 2026 Guidelines Update.

Details

This publication represents a summary of the updated 2026 European Association of Urology (EAU) Guidelines for nonmuscle-invasive bladder cancer (NMIBC), TaT1 and carcinoma in situ (CIS). The information presented herein is limited to urothelial carcinoma, unless specified otherwise.

Novel BCG Combination or Modified BCG Regimens in BCG-Naïve High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.

Details

Despite Bacillus Calmette-Guerin (BCG) remaining the standard of care for high-risk non-muscle-invasive bladder cancer (HR-NMIBC), novel combination strategies are being actively investigated. Comparative evidence on the efficacy and tolerability of these regimens in BCG-naïve patients remains limited.

Robot-Assisted Radical Cystectomy: Recommendations from Latin American Experts Consensus on Surgical Strategy, Urinary Reconstruction, and Oncological and Func-tional Outcomes.

Details

To develop contemporary evidence-informed recommendations for robot-assisted radical cystectomy (RARC), urinary reconstruction, and perioperative management, integrating current evidence with the experience of Latin American experts in uro-oncology and robotic surgery.

Oncogenic PIK3CA reprograms glutamine metabolism to drive bladder cancer progression.

Details

Genomic analysis has revealed that approximately 40% of bladder cancer (BLCA) tumors harbor alterations in the PI3K/AKT pathway, with PIK3CA mutations occurring in 15-25% of cases. PIK3CA, which encodes the catalytic p110α subunit of PI3K, plays a critical role in regulating cell survival, proliferation, and metabolism.

Integrating the Neutrophil-to-Lymphocyte Ratio into a Clinicopathological Nomogram for Event-Free Survival Prediction in Cisplatin-Treated Muscle-Invasive Bladder Cancer.

Details

Neoadjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy (RC) is a standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), yet baseline tools to refine prognostic stratification remain limited.

Substaging and Stratified Treatment of T1 Bladder Cancer - a Nationwide Register-Based Study.

Details

Substaging of T1 bladder cancer (BC) was implemented in Denmark in 2010 based on depth of lamina propria invasion-pT1a (superficial) and pT1b (deep)-with bladder-sparing therapy recommended for pT1a and early cystectomy for pT1b.

Artificial intelligence and predictive tools in non-muscle invasive bladder cancer: a narrative review of current insights and advances.

Details

Non-muscle invasive bladder cancer (NMIBC) is characterized by high recurrence rates and heterogeneous progression risk, making accurate diagnosis, risk stratification, and personalized management challenging.

Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC) - Beyond the Abstract

Details
The optimal management of muscle-invasive bladder cancer (MIBC) depends not only on selecting the appropriate therapeutic strategy but also on minimizing the time from diagnosis to the initiation of the first curative-intent treatment.

Factors Influencing Adherence to Intravesical Instillation Therapies for Non-Muscle-Invasive Bladder Cancer: A Scoping Review Protocol - Beyond the Abstract

Details
Intravesical therapy remains a cornerstone in the management of non–muscle-invasive bladder cancer (NMIBC), with Bacillus Calmette-Guérin (BCG) representing the standard of care for patients with intermediate- and high-risk disease. Despite its established efficacy, treatment is associated with a substantial patient burden related to frequent outpatient visits and a broad spectrum of local and systemic side effects. Common toxicities include lower urinary tract symptoms such as urinary frequency, urgency, dysuria, and bladder irritation, as well as fatigue, hematuria, fever, and flu-like symptoms.1
Page 1 of 1213